SAN DIEGO, May 20 /PRNewswire/ -- Biocept, Inc. ("Biocept"), an emerging leader in rare cell capture, announced today thatthe U.S. Patent and Trademark Office has issued a patent for Biocept's cell separation technology using a microfluidic device. U.S. patent #7,695,956 entitled "Device for Cell Separation and Analysis and Method of Using" protects Biocept's microflow
"This patent establishes Biocept's leadership position in using a microfluidic device to capture and analyze rare cells for prenatal or cancer applications," said Stephen M. Coutts, President and CEO of Biocept. "We are using this invention to develop innovative proprietary tests in which we capture and analyze circulating tumor cells from a blood sample from cancer patients. These circulating tumor cells provide genetic information about the patient's disease and can potentially guide the clinicians in making therapeutic choices to maximize patient response. We look forward to bringing this technology through to commercialization and making personalized medicine a reality for cancer patients and their families."
Biocept, whose focus is in cell separation technology, develops novel diagnostic assays for personalized medicine in detection and monitoring of recurrent cancer. Biocept's CEE Cell Enrichment and Extraction platform combines sophisticated attachment chemistry with mathematically modeled fluid dynamics to enable earlier, accurate and less invasive diagnoses. Isolation, purification and genetic analysis of rare cells, such as circulating tumor cells, are managed within our state-of-the-art CLIA-accredited laboratory. The clinical laboratory is accredited by the College of American Pathologists (CAP) and holds licenses in California and several other states.
SOURCE Biocept, Inc.
Subscribe to our Free Newsletters!
Neuroblastoma is a very rare type of childhood cancer that develops in immature nerve cells ...
Video-electroencephalography monitoring is a diagnostic technique that records the electrical ...View All